Mohammed Haneefa Nizamudeen/iStock via Getty Images

Verona Pharma plc (NASDAQ:VRNA) could bring the first innovative product for the treatment of COPD to market. At the end of 2022, the latest clinical trials on Ensifentrine underlined important positive results on symptoms, lung functional

CODP

Investor Presentation 2023

treatments

Investor Presentation 2023

large market

Investor Presentation 2023

COPD story

Investor Presentation 2023

potential market

Investor Presentation 2023

pipeline

Investor Presentation 2023

further market

Investor Presentation 2023

valuation

Seeking Alpha

blockbuster

Investor Presentation 2023

VRNA

VTYX

ARVN

AUPH

GLPG

Price/Book Vale (TTM)

7.53

4.94

2.70

2.60

1.16

ratings

Seeking Alpha

factor grades

Seeking Alpha

Source link